Nuvectis Pharma, Inc. (NASDAQ:NVCT) to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Nuvectis Pharma in a report released on Monday, April 8th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.38) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.22) EPS and FY2028 earnings at ($2.66) EPS.

Nuvectis Pharma Stock Down 5.4 %

NVCT opened at $7.02 on Thursday. The firm has a market capitalization of $124.75 million, a P/E ratio of -4.91 and a beta of 0.28. The stock has a fifty day moving average of $8.48 and a 200-day moving average of $8.76. Nuvectis Pharma has a 12-month low of $6.20 and a 12-month high of $18.65.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01).

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its position in Nuvectis Pharma by 216.8% during the third quarter. Tower Research Capital LLC TRC now owns 4,052 shares of the company’s stock valued at $29,000 after purchasing an additional 2,773 shares during the last quarter. Citigroup Inc. bought a new position in Nuvectis Pharma during the second quarter valued at approximately $33,000. California State Teachers Retirement System acquired a new stake in Nuvectis Pharma in the second quarter valued at approximately $36,000. Royal Bank of Canada bought a new stake in Nuvectis Pharma in the second quarter worth approximately $43,000. Finally, Wells Fargo & Company MN grew its position in Nuvectis Pharma by 11,280.0% in the second quarter. Wells Fargo & Company MN now owns 2,845 shares of the company’s stock worth $45,000 after acquiring an additional 2,820 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Insider Activity at Nuvectis Pharma

In other Nuvectis Pharma news, CEO Ron Bentsur acquired 5,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was purchased at an average cost of $10.29 per share, for a total transaction of $51,450.00. Following the transaction, the chief executive officer now owns 3,242,484 shares of the company’s stock, valued at approximately $33,365,160.36. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 38.85% of the stock is owned by insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.